Navigation Links
Codexis Announces Carbon Capture Progress at ARPA-E Summit
Date:2/28/2011

REDWOOD CITY, Calif., Feb. 28, 2011 /PRNewswire/ -- At the ARPA-E Energy Innovation Summit today in Washington, DC, Codexis, Inc. (Nasdaq: CDXS) will announce significant progress towards developing economical, commercial scale technology to reduce carbon dioxide emissions from coal-fired power plants.  The program is supported by an ARPA-E Recovery Act program grant. Coal-fired power plants are major emitters of carbon dioxide, a significant greenhouse gas.

"Current carbon capture technology is inefficient and costly, hindering large scale deployment," said Alan Shaw, Ph.D., President and Chief Executive Officer.  "It can nearly double the cost of electricity produced by a coal-fired power plant, and decrease the amount of total plant electricity output. Using Codexis technology, power plant operators may be able to use more efficient capture methods to decrease the cost of carbon capture.  This, in turn, could lead to wider adoption of this important technology solution."

The data will be presented today in a poster session and tomorrow in a presentation by James Lalonde, Ph.D., Codexis' Vice President of Biochemistry and Engineering Research and Development. Codexis is jointly developing the technology with CO2 Solution, Inc., Quebec, Canada.  

The grant supports development of custom enzymes to decrease energy needed to capture CO2 from coal-fired power plants.  Enzymes developed by Codexis under the grant have been shown to be functional and stable in relatively inexpensive and energy efficient solvents for 24 hours at temperatures up to 75 degrees Celsius.  Use of these solvents with fully developed enzymes is expected to reduce the energy needed to capture CO2 within the plant by 30%.  

This performance is essential to reaching a key goal of the program – using improved technology to reduce the incremental c
'/>"/>

SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Codexis Names Fernando Valle Research Fellow
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Codexis Expands Collaboration with Teva
4. Codexis Expands Pharmaceutical Manufacturing Partnerships
5. Codexis, Inc. Announces Pricing of Initial Public Offering
6. Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California
7. Codexis Names Peter Strumph SVP, Commercial Operations
8. Codexis to Present at the Pacific Crest Technology Leadership Forum
9. Codexis Expands Codex® Panel Product Family at CPhI
10. Codexis to Announce Third Quarter 2010 Financial Results October 28, 2010
11. Codexis to Present at Piper Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Pomerantz LLP is investigating ... ("PDL BioPharma" or the "Company") (NASDAQ: PDLI).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On September 17, 2014, the Company ...
(Date:9/17/2014)... 17, 2014  Rebiotix Inc. announced this morning that results ... candidate, RBX2660 (microbiota suspension) will be presented in two posters ... Philadelphia from October 8-12. ... poster session on Thursday, October 9, 2014: Poster: ... 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study ...
(Date:9/17/2014)... , Sept. 17, 2014  Bayer HealthCare will present ... Foundation,s 66 th Annual Meeting, which takes place ... The data, which will be shared through poster presentations, ... patient care. Data will be presented in a scientific ... treatment modalities in hemophilia A patients, Bayer is maintaining ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4
...   , Strategic collaboration with Ipsen for marketing ... Nordics and the US , Photocure to commercialise ... Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on ... of a new commercial strategy for Hexvix, its flagship product ...
... Luminex Corporation (NASDAQ: LMNX ), today ... its annual European multiplexing technology symposium, September 28-29, 2011, ... feature scientific sessions, workshops, discussion groups, exhibitions and networking ... who are performing groundbreaking work in clinical diagnostics and ...
Cached Medicine Technology:Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 2Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 3Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 4Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 5Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 6Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 7Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 8Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 2Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 3Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna 4
(Date:9/17/2014)... damage to the ends of chromosomes could hold the key ... form of skin cancer according to new research from ... an important new genetic risk factor for melanoma. , It ... strongest indicators of those most at risk of developing melanoma. ... sun, as they burn more easily. , It now appears ...
(Date:9/17/2014)... North Central Surgical Center is proud to ... their top-notch services. The hospital was the recipient for ... surgery. , Hospital-wide, North Central was the recipient of ... this award for two years in a row (2013-2014). ... the nation for Patient Safety in 2014 and ranked ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Tidewater ... host recruit757’s scholarship workshop for football players and their ... Sept. 23. , Doors open at 6:30 p.m. for ... and speak to trainers and physical therapists. The workshop ... p.m. , The Newport News Tidewater Performance Center, which ...
(Date:9/17/2014)... Positive messages about the health benefits of quitting smoking ... study suggests. Although smokers who think quitting will ... harmful effects of smoking, researchers found smokers who believe ... "gain-framed," or positive, messages about how quitting will improve ... mix of both types of messages might get more ...
(Date:9/17/2014)... FRISCO, Texas (PRWEB) September 17, 2014 ... (EV-D68) outbreak that is hospitalizing scores of infants, children ... Louisiana, says Dr. Kirk Mahon, medical director of Legacy ... , “There have been no reported cases of EV-D68 ... Oklahoma and Louisiana, that could change,” he said. “Implementing ...
Breaking Medicine News(10 mins):Health News:Chromosome buffers hold key to better melanoma understanding 2Health News:North Central Surgical Center Receives Several Accolades 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2
... Medical Transcription announced today that Administrative Advantage has chosen ZyDoc,s ... , ... Hauppauge, New York (PRWEB) May ... that Administrative Advantage , a full-service medical transcription company ...
... Robert L. Williamson III, DDS of Raleigh Comprehensive and Cosmetic Dentistry ... to earn the certification for oral sedation dentistry. , ... ... Cosmetic Dentistry, Dr. Robert L. Williamson III and Associates, announced recently ...
... Access to Pixantrone through ProgramSEATTLE, May 5 Cell ... that pixantrone is now available on a named-patient basis ... healthcare professionals for the treatment of individual patients with ... standard therapies or is refractory to them. We know ...
... to Colleges and Universities , ... Baltimore, MD. (Vocus) ... has formally completed the acquisition of CMI Insurance, formerly a PSA ... Inc., the travel medical insurance entity within MEDEX Global ...
... Growth and Effective Expense ManagementContinued Progress on Debt ReductionBIRMINGHAM, ... HLS ) today reported its results of operations for ... showed consolidated net operating revenues of $475.1 million for ... for the first quarter of 2008, or an increase ...
... Every summer, valley businesses shed their business attire in exchange ... in the spirit of raising money for United Cerebral Palsy ... disabilities. This year, the theme is Camp Casual and ... 17th though businesses can choose to hold their event on ...
Cached Medicine News:Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 2Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 3Health News:Administrative Advantage Selects ZyDoc e-Transcription Platform for Clients 4Health News:Raleigh Comprehensive and Cosmetic Dentistry Earns Certification For Sedation Dentistry 2Health News:Raleigh Comprehensive and Cosmetic Dentistry Earns Certification For Sedation Dentistry 3Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 2Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 3Health News:Pixantrone Now Available in Europe on a Named-Patient Basis 4Health News:MEDEX Acquires CMI Insurance 2Health News:MEDEX Acquires CMI Insurance 3Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 2Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 3Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 4Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 5Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 6Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 7Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 8Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 9Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 10Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 11Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 12Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 13Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 14Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 15Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 16Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 17Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 18Health News:HealthSouth Reports Strong EPS Results for First Quarter Ended March 31, 2009 19Health News:Valley Businesses Shedding Their Suits to Go Casual for a Cause 2
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
... an effort to improve on the ... toxicology, abused drugs, and immunosuppressants tests, ... which incorporates random access capabilities. Although ... undergone several important changes in the ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Medicine Products: